FDA Brief

Warning letters Drugs

FDA warning letter to

DSP Skin Care LLC

High riskIssued Jul 19, 2022Posted Aug 2, 2022Division of Pharmaceutical Quality Operations IV

FDA cites DSP Skin Care for manufacturing failures and unapproved, misbranded Hongosan antifungal drugs.

What happened

FDA inspected DSP Skin Care's Los Angeles facility from September 7 to September 9, 2021. The agency found the firm released drug products without finished-product testing, lacked a stability program to support expiration dates, and lacked an adequate quality unit and batch records. FDA also reviewed the firm's website and found the Hongosan Anti-Fungal Set marketed as an unapproved new drug with labeling that did not meet OTC monograph or Drug Facts requirements, and found the firm's establishment registration expired and its drug listings were missing or inactivated.

What FDA found

  1. DSP released Hongosan Premium Plus Spray and DSP Skin Care Hand Sanitization Gel without laboratory testing to confirm identity, strength, purity, and other quality attributes before release.

    21 CFR 211.165(a)
  2. DSP lacked an adequate stability program to show Hongosan Anti-Fungal Set and Hongosan Premium Plus Spray stay within specification through their labeled expiry of up to two years.

    21 CFR 211.166(a)
  3. DSP's quality control unit lacked written procedures and authority, and the firm could not provide batch production records with lot numbers for about 20 batches of Hongosan Anti-Fungal Cream and Hongosan Premium Plus liquid.

    21 CFR 211.22
  4. DSP marketed Hongosan Anti-Fungal Set as an unapproved new drug because its combined use and claims did not meet OTC topical antifungal monograph M005 and no FDA-approved application was in effect.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  5. Hongosan Anti-Fungal Set's Drug Facts label omitted the active ingredient undecylenic acid and did not use the required "Inactive ingredients" heading, making it misbranded.

    21 CFR 201.66(c)(2), (c)(8); FD&C Act section 502(a), (c)
  6. DSP's establishment registration expired on December 31, 2017, and its Hongosan products were not properly listed or certified with FDA, making the drugs misbranded.

    FD&C Act sections 510(b), (j), 502(o); 21 CFR Part 207

What FDA wants

FDA tells DSP to correct its CGMP failures, stop marketing the unapproved and misbranded Hongosan products, and register and list its drugs. FDA asks for a written response within 15 working days.

Who should pay attention

  • retailers and online sellers of Hongosan products
  • contract manufacturers and packagers used by DSP
  • OTC drug firms with expired registrations or missing listings

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk